Costs by Site of Service for Commercially-Insured Patients with Metastatic Pancreatic Cancer Receiving Guideline-Recommended Chemotherapy: Comparing Community Oncology and Hospital Outpatient Settings

References

• American Cancer Society. Key statistics for pancreatic cancer. Available from: https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html. Accessed September 27, 2022.
   Google Scholar
• Lambert A, Gavoille C, Conroy T. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol. 2017;10(8):631–645. doi:10.1177/1756283X17713879
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442
   PubMed Web of Science ®Google Scholar
• Khanal N, Upadhyay S, Dahal S, Bhatt VR, Silberstein PT. Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base. Ther Adv Med Oncol. 2015;7(4):198–205. doi:10.1177/1758834015579313
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines for patients: pancreatic cancer. Plymouth Meeting: NCCN Foundation; 2019.
   Google Scholar
• Aditi K, Chia Jie T, Manit S, et al. Survival benefits and safety of chemotherapy regimens for pancreatic cancer: an umbrella review of meta-analyses of randomized controlled trials. Ann Pancreatic Disorders Treatment. 2022;4(1):001–020. doi:10.17352/apdt.000008
   Google Scholar
• Kharat A, Brendle M, Chhibber A, Chaiyakunapruk N, Biskupiak J. Comparative safety and efficacy of therapeutic options in resectable and advanced/metastatic pancreatic cancer: a systematic review and indirect comparison. Oncol Res Treat. 2021;44(9):476–484. doi:10.1159/000517409
   PubMed Web of Science ®Google Scholar
• Winn AN, Keating NL, Trogdon JG, Basch EM, Dusetzina SB. Spending by commercial insurers on chemotherapy based on site of care, 2004–2014. JAMA Oncol. 2018;4(4):580–581. doi:10.1001/jamaoncol.2017.5544
   PubMed Web of Science ®Google Scholar
• Gordan LN, Blazer M, Xcenda B. Site of care cost analysis 2017; 2017. Available from: https://www.communityoncology.org/wp-content/uploads/2018/08/Site-of-Care-Cost-Analysis-White-Paper_9.25.17.pdf. Accessed September 27, 2022.
   Google Scholar
• Hayes J, Hoverman RJ, Brow ME, et al. Cost differential by site of service for cancer patients receiving chemotherapy. Am J Manag Care. 2015;21(3):e189–96.
   PubMed Web of Science ®Google Scholar
• Higgins A, Veselovskiy G, Schinkel J. National estimates of price variation by site of care. Am J Manag Care. 2016;22(3):e116–21.
   PubMed Web of Science ®Google Scholar
• Congressional Budget Office. The prices that commercial health insurers and medicare pay for hospitals’ and physicians’ services; 2018. Available from: www.cbo.gov/publication/57422. Accessed September 27, 2022.
   Google Scholar
• NCCN. About NCCN. Available from: https://www.nccn.org/about/default.aspx. Accessed December 3, 2020.
   Google Scholar
• NCCN. NCCN guidelines® & clinical resources. Available from: https://www.nccn.org/professionals/. Accessed December 3, 2020.
   Google Scholar
• Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson comorbidity index: ICD-9 update and ICD-10 translation. Am Heal Drug Benefits. 2019;12(4):188–197.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8–35. doi:10.1159/000521288
   PubMed Web of Science ®Google Scholar
• Wilson DJ. The harmonic mean p-value for combining dependent tests. Proc Natl Acad Sci U S A. 2019;116(4):1195–1200. doi:10.1073/pnas.1814092116
   PubMed Web of Science ®Google Scholar
• Code of federal regulations 45 CFR 46.104(a). Available from: https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.104. Accessed May 24, 2022.
   Google Scholar
• Fitch K, Pelizzari PM, Pyenson B. Cost drivers of cancer care: a retrospective analysis of medicare and commercially insured population claim data; 2016:40. Available from: http://www.milliman.com/uploadedFiles/insight/2016/trends-in-cancer-care.pdf. Accessed May 24, 2022.
   Google Scholar
• Robinson JC, Whaley CM, Brown TT. Price differences to insurers for infused cancer drugs in hospital outpatient departments and physician offices. Health Aff. 2021;40(9):1395–1401. doi:10.1377/hlthaff.2021.00211
   Web of Science ®Google Scholar
• Avalere Health. Medicare payment differentials across outpatient settings of care; 2016:1–43. Available from: http://www.physiciansadvocacyinstitute.org/Portals/0/assets/docs/Payment-Differentials-Across-Settings.pdf. Accessed September 27, 2022.
   Google Scholar
• Wynn BO, Hilborne LEEH, Hussey P, Sloss EM. Medicare payment differentials across ambulatory settings; 2008.
   Google Scholar
• Lopez E. How much more than medicare do private insurers pay? A review of the literature. Available from: https://www.kff.org/medicare/issue-brief/how-much-more-than-medicare-do-private-insurers-pay-a-review-of-the-literature/. Accessed September 27, 2022.
   Google Scholar
• American Hospital Association. Fact sheet: the 340B drug pricing program; 2021. Available from: https://www.aha.org/system/files/media/file/2019/03/fact-sheet-340b-drug-pricinig-program-0119.pdf. Accessed September 27, 2022.
   Google Scholar
• Winegarden W. Addressing the problems of abuse in the 340B drug pricing program; 2017. Available from: www.pacificresearch.org. Accessed September 27, 2022.
   Google Scholar
• Desai S, McWilliams JM. Consequences of the 340B drug pricing program. N Engl J Med. 2018;378(6):539–548. doi:10.1056/NEJMsa1706475
   PubMed Web of Science ®Google Scholar
• Natalie Trebes CK& LC. Payers are shifting where patients receive infusions. Here’s what that means for 4 key industry players. Available from: https://www.advisory.com/blog/2020/10/infusion-site-of-care. Accessed December 8, 2022.
   Google Scholar
• Cigna. Medication administration site of care; 2022:1–2. Available from: https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ph_1605_coveragepositioncriteria_site_of_care.pdf. Accessed September 27, 2022.
   Google Scholar
• Aetna. Drug infusion/injection site of care policy. Available from: https://www.aetna.com/health-care-professionals/utilization-management/drug-infusion-site-of-care-policy.html. Accessed December 8, 2022.
   Google Scholar
• AJMC. Preferred site of care and coverage for infusions. Available from: https://www.ajmc.com/view/preferred-site-of-care-and-coverage-for-infusions. Accessed December 8, 2022.
   Google Scholar
• Desai SM, Hatfield LA, Hicks AL, Chernew ME, Ateev Mehrotra ADS. What are the potential savings from steering patients to lower-priced providers? A Static Analysis. Am J Manag Care. 2019;25:e204–e210.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. About the CMS innovation center. Available from: https://innovation.cms.gov/about. Accessed August 11, 2022.
   Google Scholar
• Centers for Medicare & Medicaid Services. Strategic direction. Available from: https://innovation.cms.gov/strategic-direction. Accessed August 11, 2022.
   Google Scholar